GenMark Diagnostics, Inc. (NASDAQ:GNMK) SVP Jennifer Anne Williams sold 38,681 shares of the company’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $9.08, for a total transaction of $351,223.48. Following the completion of the sale, the senior vice president now owns 155,889 shares in the company, valued at approximately $1,415,472.12. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) traded down 2.94% during midday trading on Friday, reaching $8.92. 1,126,429 shares of the company’s stock traded hands. The firm’s 50-day moving average is $9.94 and its 200 day moving average is $11.89. The firm’s market cap is $487.63 million. GenMark Diagnostics, Inc. has a 52-week low of $8.88 and a 52-week high of $13.67.

GenMark Diagnostics (NASDAQ:GNMK) last issued its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). The firm had revenue of $12.36 million during the quarter, compared to the consensus estimate of $12.44 million. GenMark Diagnostics had a negative return on equity of 109.89% and a negative net margin of 111.96%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.30) EPS. Equities research analysts expect that GenMark Diagnostics, Inc. will post ($1.06) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “GenMark Diagnostics, Inc. (GNMK) SVP Jennifer Anne Williams Sells 38,681 Shares” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/16/genmark-diagnostics-inc-gnmk-svp-jennifer-anne-williams-sells-38681-shares.html.

GNMK has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $15.00 target price (down previously from $17.00) on shares of GenMark Diagnostics in a report on Wednesday. BTIG Research restated a “buy” rating and issued a $13.00 target price on shares of GenMark Diagnostics in a report on Thursday, August 31st. Canaccord Genuity restated a “buy” rating and issued a $14.00 target price (down previously from $17.00) on shares of GenMark Diagnostics in a report on Monday, August 7th. ValuEngine upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BidaskClub upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $14.60.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlueCrest Capital Management Ltd bought a new position in shares of GenMark Diagnostics in the second quarter worth approximately $126,000. Legal & General Group Plc lifted its stake in shares of GenMark Diagnostics by 2.1% in the second quarter. Legal & General Group Plc now owns 11,521 shares of the medical equipment provider’s stock worth $137,000 after buying an additional 240 shares in the last quarter. Susquehanna International Group LLP bought a new position in shares of GenMark Diagnostics in the second quarter worth approximately $137,000. Airain ltd bought a new position in shares of GenMark Diagnostics in the first quarter worth approximately $159,000. Finally, Quantitative Systematic Strategies LLC lifted its stake in shares of GenMark Diagnostics by 18.4% in the second quarter. Quantitative Systematic Strategies LLC now owns 13,147 shares of the medical equipment provider’s stock worth $159,000 after buying an additional 2,047 shares in the last quarter.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.